February 17, 2026

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.

Both abstracts are scheduled for presentation in the *Experimental and Molecular Therapeutics* category under the session titled **Radiopharmaceutical Platforms for Theranostic Precision Oncology** on April 21, 2026.

In accordance with AACR embargo policies, details of the abstracts, including titles and full

text, will become publicly available on March 17, 2026, at 4:30 PM ET via the AACR Online Program Planner.

Presentation Details

Presentation #1:

Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 18
Poster Number: 5824

Presentation #2:

Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 21
Poster Number: 5827

Actinium's Platform Strategy for Long-Term Value Creation

The AACR 2026 data will highlight Actinium's differentiated biology-driven approach to targeted radiotherapy development including:

- Targeting resistance-associated biology rather than tumor surface expression alone
- Leveraging the high-linear energy transfer (LET) of Ac-225 to deliver potent, tumor-specific cytotoxicity
- Building a radiotherapy franchise comprised of multiple pan-tumor assets

Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, commented, "We are pleased to have two abstracts accepted for presentation at AACR 2026. Participation in this meeting provides an important opportunity to engage with the Oncology research community. We look forward to sharing additional details once the abstracts are publicly released in accordance with AACR guidelines."

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. ATNM-400, Actinium's lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes directly to disease progression, poorer survival outcomes, and continues to be expressed at a high level even after androgen receptor inhibitor (ARPI) and Pluvicto® treatment. ATNM-400 is supported by preclinical data demonstrating tumor-specific uptake, higher efficacy than androgen receptor inhibitor enzalutamide (Xtandi®) and

177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide. In NSCLC, ATNM-400 showed superior efficacy to EGFR targeting therapies including osimertinib (TARGRISSO®, AstraZeneca), Dato-DXd (DATROWAY®, AstraZeneca/Daiichi Sankyo) and amivantamab (RYBREVANT®, J&J) with synergistic activity in combination with osimertinib. In breast cancer, ATNM-400 works as monotherapy in triple-negative breast cancer, hormone-positive breast cancer and also in HER2-therapy trastuzumab (HERCEPTIN® Roche) resistant breast cancer and endocrine therapy-resistant breast cancer models. The data generated to date with ATNM-400 supports its potential across treatment settings to be used either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds approximately 240 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials,

actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:
investorrelations@actiniumpharma.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting-302689485.html

SOURCE Actinium Pharmaceuticals, Inc.